Bristol Myers Squibb (CELG-RI) Prepaid Assets (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Prepaid Assets of $4.6 billion for Q1 2026, down 16.93% YoY from $5.5 billion in Q1 2025, and little changed sequentially from $4.6 billion in Q4 2025.
Bristol Myers Squibb (CELG-RI) Prepaid Assets (2009 - 2026) Analysis & Trends
Bristol Myers Squibb has disclosed Prepaid Assets across 18 years of filings, most recently posting $4.6 billion for Q1 2026.
- In Q1 2026, Prepaid Assets fell 16.93% year-over-year to $4.6 billion; the TTM figure through Mar 2026 stood at $4.6 billion (down 16.93% YoY), while the FY2025 annual figure was $4.6 billion, down 17.87% from the prior year.
- Prepaid Assets was little changed at $4.6 billion in Q1 2026, from $4.6 billion in the prior quarter.
- Over the last five years, Prepaid Assets for CELG-RI reached as high as $7.2 billion in Q3 2023 and fell as low as $4.5 billion in Q1 2022.
- The 5-year median for Prepaid Assets is $5.6 billion (2024), against an average of $5.6 billion.
- Annual changes were most pronounced in 2022 — Prepaid Assets soared 39.11% — and 2024, when it fell 21.98%.
- A 5-year view of Prepaid Assets shows it stood at $5.8 billion in 2022, then increased by 1.93% to $5.9 billion in 2023, then retreated by 4.91% to $5.6 billion in 2024, then slipped by 17.87% to $4.6 billion in 2025, then dropped by 0.35% to $4.6 billion in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $4.6 billion, $4.6 billion, and $4.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Bristol Myers Squibb | 244.56 Mn | -10.21 Bn | 8.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.60 Bn |
| Dec 31, 2025 | 4.61 Bn |
| Sep 30, 2025 | 4.95 Bn |
| Jun 30, 2025 | 5.47 Bn |
| Mar 31, 2025 | 5.53 Bn |
| Dec 31, 2024 | 5.62 Bn |
| Sep 30, 2024 | 5.62 Bn |
| Jun 30, 2024 | 5.74 Bn |
| Mar 31, 2024 | 5.57 Bn |
| Dec 31, 2023 | 5.91 Bn |
| Sep 30, 2023 | 7.21 Bn |
| Jun 30, 2023 | 6.87 Bn |
| Mar 31, 2023 | 5.16 Bn |
| Dec 31, 2022 | 5.80 Bn |
| Sep 30, 2022 | 6.08 Bn |
| Jun 30, 2022 | 5.76 Bn |
| Mar 31, 2022 | 4.54 Bn |
| Dec 31, 2021 | 4.83 Bn |
| Sep 30, 2021 | 4.37 Bn |
| Jun 30, 2021 | 5.04 Bn |